Page 48 - Read Online

Page 14 of 17 Nasr et al. Metab Target Organ Damage 2023;3:19 https://dx.doi.org/10.20517/mtod.2023.20

80. Laharie D, Seneschal J, Schaeverbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients
treated with methotrexate for chronic inflammatory diseases: a case-control study. J Hepatol 2010;53:1035-40. DOI PubMed
81. Choi Y, Lee CH, Kim IH, Park EH, Park S, Yoo WH. Methotrexate use does not increase the prevalence of hepatic steatosis: a real-
world retrospective nested case-control study. Clin Rheumatol 2021;40:2037-45. DOI
82. Tomaszewski M, Dahiya M, Mohajerani SA, et al. Hepatic steatosis as measured by the computed attenuation parameter predicts
fibrosis in long-term methotrexate use. Can Liver J 2021;4:370-80. DOI PubMed PMC
83. Erre GL, Castagna F, Sauchella A, et al. Prevalence and risk factors of moderate to severe hepatic steatosis in patients with
rheumatoid arthritis: an ultrasonography cross-sectional case-control study. Ther Adv Musculoskelet Dis
2021;13:1759720X211042739. DOI PubMed PMC
84. Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, Clinical Practice Guideline Panel: Chair:, Panel
members, EASL Governing Board representative:. EASL clinical practice guidelines: drug-induced liver injury. J Hepatol
2019;70:1222-61. DOI
85. Lee B, Jung EA, Yoo JJ, et al. Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: a
systematic review and meta-analysis. Liver Int 2020;40:1344-55. DOI PubMed
86. Lelliott CJ, López M, Curtis RK, et al. Transcript and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of
fatty acid synthesis in the presence of hepatic steatosis. FASEB J 2005;19:1108-19. DOI
87. Gudbrandsen OA, Rost TH, Berge RK. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J
Lipid Res 2006;47:2223-32. DOI
88. Cole LK, Jacobs RL, Vance DE. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid
synthesis. Hepatology 2010;52:1258-65. DOI PubMed
89. Bruno S, Maisonneuve P, Castellana P, et al. Incidence and risk factors for non-alcoholic steatohepatitis: prospective study of 5408
women enrolled in Italian tamoxifen chemoprevention trial. BMJ 2005;330:932. DOI PubMed PMC
90. Elefsiniotis IS, Pantazis KD, Ilias A, et al. Tamoxifen induced hepatotoxicity in breast cancer patients with pre-existing liver
steatosis: the role of glucose intolerance. Eur J Gastroen Hepat 2004;16:593-8. DOI
91. Osman KA, Osman MM, Ahmed MH. Tamoxifen-induced non-alcoholic steatohepatitis: where are we now and where are we going?
Expert Opin Drug Saf 2007;6:1-4. DOI PubMed
92. Staa TP, Leufkens HG, Abenhaim L, Begaud B, Zhang B, Cooper C. Use of oral corticosteroids in the United Kingdom. QJM
2000;93:105-11. DOI PubMed
93. Overman RA, Yeh JY, Deal CL. Prevalence of oral glucocorticoid usage in the United States: a general population perspective.
Arthritis Care Res 2013;65:294-8. DOI PubMed
94. Tarantino G, Finelli C. Pathogenesis of hepatic steatosis: the link between hypercortisolism and non-alcoholic fatty liver disease.
World J Gastroenterol 2013;19:6735-43. DOI PubMed PMC
95. Rahimi L, Rajpal A, Ismail-Beigi F. Glucocorticoid-induced fatty liver disease. Diabetes Metab Syndr Obes 2020;13:1133-45. DOI
PubMed PMC
96. Buzzetti E, Pinzani M, Tsochatzis EA. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD). Metabolism
2016;65:1038-48. DOI PubMed
97. Li JX, Cummins CL. Fresh insights into glucocorticoid-induced diabetes mellitus and new therapeutic directions. Nat Rev Endocrinol
2022;18:540-57. DOI PubMed PMC
98. Rockall AG, Sohaib SA, Evans D, et al. Hepatic steatosis in cushing's syndrome: a radiological assessment using computed
tomography. Eur J Endocrinol 2003;149:543-8. DOI
99. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-Meta-
analytic assessment of prevalence, incidence, and outcomes. Hepatology 2016;64:73-84. DOI PubMed
100. Hubel JM, Schmidt SA, Mason RA, et al; EMIL-Study Group. Influence of plasma cortisol and other laboratory parameters on
nonalcoholic Fatty liver disease. Horm Metab Res 2015;47:479-84. DOI
101. Pagano G, Cavallo-Perin P, Cassader M, et al. An in vivo and in vitro study of the mechanism of prednisone-induced insulin
resistance in healthy subjects. J Clin Invest 1983;72:1814-20. DOI PubMed PMC
102. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes
Care 2006;29:2728-9. DOI
103. Negro F. Abnormalities of lipid metabolism in hepatitis C virus infection. Gut 2010;59:1279-87. DOI PubMed
104. Mihm S, Fayyazi A, Hartmann H, Ramadori G. Analysis of histopathological manifestations of chronic hepatitis C virus infection
with respect to virus genotype. Hepatology 1997;25:735-9. DOI PubMed
105. Patton HM, Patel K, Behling C, et al. The impact of steatosis on disease progression and early and sustained treatment response in
chronic hepatitis C patients. J Hepatol 2004;40:484-90. DOI
106. Rubbia-Brandt L, Quadri R, Abid K, et al. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J Hepatol
2000;33:106-15. DOI
107. Adinolfi LE, Gambardella M, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of
chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology 2001;33:1358-64. DOI
PubMed
108. Kumar D, Farrell GC, Fung C, George J. Hepatitis C virus genotype 3 is cytopathic to hepatocytes: reversal of hepatic steatosis after